Moderna, Inc. (NASDAQ:MRNA)’s stock price rose 5.2% during trading on Friday . The company traded as high as $98.43 and last traded at $97.61. Approximately 15,197,944 shares changed hands during trading, a decline of 8% from the average daily volume of 16,531,182 shares. The stock had previously closed at $92.77.
MRNA has been the topic of a number of research reports. BMO Capital Markets lowered shares of Moderna from an “outperform” rating to a “market perform” rating and set a $109.00 target price on the stock. in a research report on Tuesday, November 17th. Argus increased their price objective on shares of Moderna from $80.00 to $88.00 and gave the company a “buy” rating in a research note on Wednesday, November 11th. BidaskClub upgraded shares of Moderna from a “hold” rating to a “buy” rating in a research note on Thursday, September 17th. JPMorgan Chase & Co. reiterated a “hold” rating on shares of Moderna in a research note on Thursday, August 6th. Finally, Zacks Investment Research upgraded shares of Moderna from a “sell” rating to a “hold” rating and set a $100.00 price objective on the stock in a research note on Wednesday. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and fourteen have assigned a buy rating to the stock. Moderna has an average rating of “Buy” and an average price target of $94.22.
The company’s 50 day moving average price is $74.89 and its 200 day moving average price is $68.62. The company has a quick ratio of 17.30, a current ratio of 2.43 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $38.63 billion, a price-to-earnings ratio of -60.25 and a beta of 0.53.
In related news, President Stephen Hoge sold 20,000 shares of the firm’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $64.99, for a total transaction of $1,299,800.00. Following the completion of the transaction, the president now owns 1,966,530 shares of the company’s stock, valued at $127,804,784.70. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, General Counsel Lori M. Henderson sold 32,000 shares of the firm’s stock in a transaction on Wednesday, October 21st. The stock was sold at an average price of $70.16, for a total transaction of $2,245,120.00. The disclosure for this sale can be found here. Insiders have sold 632,292 shares of company stock valued at $44,080,587 over the last quarter. Insiders own 29.20% of the company’s stock.
Institutional investors have recently modified their holdings of the stock. Huntington National Bank raised its holdings in shares of Moderna by 250.0% during the third quarter. Huntington National Bank now owns 350 shares of the company’s stock worth $25,000 after purchasing an additional 250 shares during the last quarter. Clearstead Advisors LLC raised its stake in shares of Moderna by 733.3% in the 3rd quarter. Clearstead Advisors LLC now owns 375 shares of the company’s stock valued at $27,000 after acquiring an additional 330 shares during the period. Prestige Wealth Management Group LLC raised its stake in shares of Moderna by 100.0% in the 3rd quarter. Prestige Wealth Management Group LLC now owns 400 shares of the company’s stock valued at $28,000 after acquiring an additional 200 shares during the period. Bessemer Group Inc. purchased a new stake in shares of Moderna in the 2nd quarter valued at approximately $27,000. Finally, Trust Co. of Vermont raised its stake in shares of Moderna by 214.3% in the 3rd quarter. Trust Co. of Vermont now owns 440 shares of the company’s stock valued at $31,000 after acquiring an additional 300 shares during the period. 55.04% of the stock is owned by hedge funds and other institutional investors.
Moderna Company Profile (NASDAQ:MRNA)
Moderna, Inc, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.
Further Reading: The risks of owning bonds
Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.